Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as ...

Several French companies have committed to making new investments in the Egyptian market across various sectors, including ...

Bidders for Sanofi’s consumer healthcare unit are revising their offers in part to address concerns around potential ...

Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold ...

IMTOZ trial findings and subsequent approval of Isa-VRd regimen for transplant-ineligible myeloma suggested the combo as a ...

The deal includes additional commercial milestone payments of up to $250 million and will be completed by year-end, subject ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €100.00.

France stocks were mixed after the close on Monday, as gains in the Consumer Goods, Technology and Healthcare sectors led ...

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on ...

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...

Dupixent approved in the US as the first-ever biologic medicine for patients with COPD         Dupixent is indicated for the approximately 300,000 adults in the US with inadequately ...

PARIS, France and TARRYTOWN, NY, USA I7, 2024 I The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on ...